What is HC Wainwright's Estimate for KROS FY2026 Earnings?

Key Points

• HC Wainwright raised its FY2026 estimate to a loss of $3.33 per share from a loss of $4.62, while maintaining a Buy rating and $20 price target. Its estimate is less negative than the consensus forecast of a $5.27-per-share loss.
• Keros reported quarterly earnings of $0.70 per share, beating expectations for a $0.96 loss; revenue of $40.01 million also exceeded the $14.76 million forecast.
• Across analysts, Keros has an average Hold rating and a consensus price target of $21.40. Shares opened at $9.17, near their 52-week low of $9.10.

Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities researchers at HC Wainwright lifted their FY2026 earnings estimates for Keros Therapeutics in a research note issued to investors on Friday, November 6th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($3.33) per share for the year, up from their previous forecast of ($4.62). HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. The consensus estimate for Keros Therapeutics' current full-year earnings is ($5.27) per share. HC Wainwright also issued estimates for Keros Therapeutics' Q4 2026 earnings at ($1.39) EPS, Q1 2027 earnings at ($1.45) EPS, Q2 2027 earnings at ($1.52) EPS, Q3 2027 earnings at ($0.62) EPS, Q4 2027 earnings at ($1.65) EPS, FY2027 earnings at ($5.25) EPS, FY2028 earnings at ($5.86) EPS, FY2029 earnings at ($3.55) EPS and FY2030 earnings at ($1.15) EPS.

A number of other research firms also recently weighed in on KROS. Leerink Partners dropped their target price on Keros Therapeutics from $30.00 to $23.00 and set an "outperform" rating for the company in a research report on Tuesday, August 4th. Wells Fargo & Company lowered their price objective on Keros Therapeutics from $20.00 to $18.00 and set an "overweight" rating for the company in a research report on Tuesday, August 4th. Zacks Research upgraded Keros Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Thursday, August 27th. Wall Street Zen raised Keros Therapeutics from a "strong sell" rating to a "hold" rating in a report on Monday. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Keros Therapeutics in a research report on Wednesday, August 12th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $21.40.

Keros Therapeutics Trading Down 2.0%

Shares of KROS opened at $9.17 on Tuesday. The business's fifty day moving average price is $11.14 and its two-hundred day moving average price is $11.87. Keros Therapeutics has a 52 week low of $9.10 and a 52 week high of $22.55.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of ($0.96) by $1.66. Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. The firm had revenue of $40.01 million during the quarter, compared to analysts' expectations of $14.76 million.

Institutional Investors Weigh In On Keros Therapeutics

Several large investors have recently made changes to their positions in the stock. Man Group plc acquired a new stake in shares of Keros Therapeutics in the second quarter valued at about $1,664,000. Nantahala Capital Management LLC bought a new position in shares of Keros Therapeutics during the second quarter worth about $15,091,483. Empowered Funds LLC bought a new position in shares of Keros Therapeutics during the second quarter worth about $1,521,000. ADAR1 Capital Management LLC acquired a new position in shares of Keros Therapeutics in the second quarter worth approximately $2,641,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Keros Therapeutics by 453.9% in the first quarter. Dimensional Fund Advisors LP now owns 321,360 shares of the company's stock worth $3,547,000 after acquiring an additional 263,347 shares during the period. Institutional investors and hedge funds own 71.56% of the company's stock.

Insider Activity

In related news, insider Lorena Raquel Lerner sold 3,568 shares of Keros Therapeutics stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total value of $36,714.72. Following the sale, the insider owned 27,559 shares of the company's stock, valued at approximately $283,582.11. This trade represents a 11.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 5,343 shares of company stock valued at $54,985. Company insiders own 12.60% of the company's stock.

Keros Therapeutics announced that its Board of Directors has approved a stock buyback plan on Wednesday, September 9th that authorizes the company to buy back $5 million in shares. This repurchase authorization authorizes the company to repurchase up to 2.3% of its shares through open market purchases. Stock repurchase plans are usually an indication that the company's leadership believes its stock is undervalued.

Keros Therapeutics News Summary

Here are the key news stories impacting Keros Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $3.33 from a loss of $4.62, and its FY2027 estimate to a loss of $5.25 from a loss of $6.39. It also modestly improved its Q4 2026 forecast. The firm maintained a Buy rating and $20 price target. Keros Therapeutics analyst information
• Neutral Sentiment: Wall Street Zen upgraded KROS to Hold, a modestly improved rating that is less bullish than a Buy recommendation. Keros Therapeutics upgraded to Hold at Wall Street Zen
• Negative Sentiment: Despite the near-term upward revisions, HC Wainwright lowered its EPS forecasts for FY2028, FY2029 and FY2030. Its estimates still imply losses in each of those years, signaling that profitability remains a long-term challenge.

About Keros Therapeutics

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-β) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function.

Keros' investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.